Loading
ST
Sage Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Aug 2023.
Sage Therapeutics, Inc.: what insiders have been doing
Sage Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Sage Therapeutics, Inc. The previous disclosure was published on 31 July 2025.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
78
Thresholds
n/a
Buy Volume
€3M
10 ops. · all time
Sell Volume
n/a
3 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$35.5M
Net income-US$345M-971.5% margin
Last declaration on 31 July 2025
Declarations78 total
46,940 sharesCommon StockSEC:0000950170-25-100636:0
24,999 sharesCommon StockSEC:0000950170-25-100700:0
28,053 sharesCommon StockSEC:0000950170-25-100689:0
3,000 sharesCommon StockSEC:0000950170-25-100675:0
8,000 sharesCommon StockSEC:0000950170-25-100666:0
2,845 sharesCommon StockSEC:0000950170-25-100653:0
7,215 sharesCommon StockSEC:0000950170-25-100643:0
113 shares@ US$9.22100.0% of flowCommon StockSEC:0001562180-25-005087:0
79 shares@ US$9.222.8% of flowCommon StockSEC:0001562180-25-005086:0
19,964 shares0Common StockSEC:0001562180-25-003112:0
933 shares0Common StockSEC:0001562180-25-003113:0
3,255 shares0Common StockSEC:0001562180-25-003114:0
525 shares0Common StockSEC:0001562180-25-003111:0
2,000 shares0Common StockSEC:0001562180-25-002905:0
79 shares@ US$8.212.8% of flowCommon StockSEC:0001562180-25-002756:0
2,502 shares@ US$7.4983.2% of flowCommon StockSEC:0001562180-25-001614:0
685 shares@ US$7.18100.0% of flowCommon StockSEC:0001562180-25-001201:0
376 shares@ US$7.1812.1% of flowCommon StockSEC:0001562180-25-001200:0
822 shares@ US$7.18100.0% of flowCommon StockSEC:0001562180-25-001202:0
14,000 shares0Common StockSEC:0001562180-25-000438:0
20,000 shares0Common StockSEC:0001562180-25-000435:0
24,000 shares0Common StockSEC:0001562180-25-000436:0
79 shares@ US$5.481.9% of flowCommon StockSEC:0001562180-24-008597:0
6,250 shares0Common StockSEC:0001562180-24-007692:0
5,000 shares0Common StockSEC:0001562180-24-007490:0
25 of 78 declarations
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States. Founded in 2010 as Sterogen Biopharma, Inc. and renamed Sage Therapeutics in 2011, the company is headquartered in Cambridge, Massachusetts. Sage focuses on central nervous system disorders, with a particular emphasis on neuroscience and mental health. Its strategy is built around discovering, developing, and where possible commercializing therapies that modulate key neurobiological pathways, especially the GABA and NMDA receptor systems.
Sage’s business has historically been organized around a small but highly specialized portfolio of commercial and clinical-stage assets. Its most important commercial product is ZURZUVAE (zuranolone), which was approved by the FDA in August 2023 for the treatment of postpartum depression in adults. Sage began generating ZURZUVAE revenue in late 2023 through its U.S. collaboration with Biogen, making it the company’s primary monetization engine. The company also previously marketed ZULRESSO (brexanolone), but discontinued U.S. commercial availability at the end of 2024 and later withdrew the NDA in 2025, reflecting a sharper focus on the product with the strongest commercial potential.
Read moreShow less
From a competitive standpoint, Sage is a niche CNS specialist rather than a diversified pharmaceutical player. Its main differentiator is scientific depth and the oral profile of ZURZUVAE in a historically underserved indication. At the same time, the company operates in a challenging competitive landscape, where larger pharmaceutical groups and emerging biotech peers are pursuing alternative approaches in psychiatry and neurology. Sage’s pipeline has also experienced several clinical setbacks, which has reduced visibility on its longer-term standalone growth profile.
Geographically, Sage remains largely U.S.-centered in both operations and initial commercialization. Its international footprint is more reliant on collaborations and potential regulatory expansion than on a broad global infrastructure. Recent notable developments include the ramp-up of ZURZUVAE, the exit of ZULRESSO from the U.S. market, pipeline restructuring during 2025, and the announcement in June 2025 of an acquisition agreement by Supernus Pharmaceuticals. Taken together, these events place Sage Therapeutics in a transitional phase, with the Nasdaq-listed company evolving from a development-heavy CNS biotech toward a transaction-driven strategic outcome.
